To determine the prevalence and the antibiotic resistant patterns of the multi-drug resistant Extended-Spectrum Β-Lactamase(ESBL) producing E. coli isolates from children urine samples, in Queen Rania Al-Abdullah Hospital for children.A total of 61 non-repetitive urine samples from various outpatient clinics and inpatient wards were collected retrospectively over a period of 5 months (May 2012 to September 2012). The resistant patterns, screening and confirmatory tests for phenotypic detection of ESBL-producers were studied using the VITEK 2 system against a set of antibiotics found on the antimicrobial susceptibility extend card AST-EXN8.Children were nearly equally infected by both types of E. coli isolates, ESBL-producers 31 (50.8%) and non ESBL-producers 30 (49.2%). ESBL-producing E. coli showed maximum rate resistance to Cefuroxime and Piperacillin (100%), Aztreonam, Cefixime, Ceftriaxone plus Levofloxacin (96.8%), Ampicillin/Sulbactam and Cefepime (93.5%), and Moxifloxacin (90.3%), while minimum resistance rate was seen with Tigecycline (12.9%), Colistin (3.2%) and meropenem (0%). ESBL-producing isolates were significantly more resistant than Non-ESBL-producers (p < 0.05) to the following antimicrobials (Ampicillin/Sulbactam, Aztreonam, Cefepime, Cefixime, Ceftriaxone, Levofloxacin, Moxifloxacin, Piperacillin and Tetracycline). Multi-drug resistance was found to be higher in ESBL-producing isolates, which were resistant to at least 9 antibiotics. To limit the spread of the multi-drug resistant ESBL-producers E. coli isolates, we should perform screening test for these isolates on daily basis, isolate the infected patients and choose the best therapeutic option.According to the resistant pattern and safety issue, Morepenem can be considered as first line treatment and colistin as last resort therapy.
INTRODUCTION
xtended-spectrum β-lactamases (ESBLs) are a group of β-lactamases enzymes belongs to group 2be produced by Gram negative Enterobacteriaceae (such as Klebsiellaspp and Escherichia coli).
1 Due to rapid emerge of ESBL producing uropathogens over the last decade the antimicrobial susceptibility profile have been changed dramatically.
2-5 ß-lactams antimicrobial agents are among the most widely used antibiotics to treat those community and hospital acquired infections. 6, 7 All ESBLs producers share the resistant to all generations of cephalosporins, penicillins, and aztreonam (except for cephamycins or carbapenems) and inhibited by clavulanic acid. [8] [9] [10] [11] [12] Community acquired or nosocomial Urinary Tract Infections (UTI) are one of the common bacterial infections in childhood period.
13,14 ESBLproducers isolates can lead to UTI that range from uncomplicated to life threatening UTI in both developed and developing countries. 15, 17 Morbidity and mortality usually increased when subjects with UTI were treated by antibiotics with inadequate in vitro activity against these ESBLs producing isolates, for that a rapid and accurate detection of these isolates is essential for effective treatment. 18, 19 The increasing prevalence of UTI caused by ESBL-producing E. coli worldwide makes empirical treatment by conventional and newer antimicrobial agents is quite difficult 5, [19] [20] [21] The aims of this study were to determine the prevalence and antibiotic resistant patterns of ESBL-producing E. coli isolates from urine cultures, in Queen Rania Al-Abdullah Hospital (QRAH) for children, King Hussein Medical Center, Amman-Jordan, using the VITEK 2 system.
SUBJECTS AND METHODS

Bacterialisolates
In a retrospective study, A total of sixty one nonrepetitive urine samples which were obtained from various outpatient clinics and inpatient wards of QRAH for children over a period of 5 months (May 2012 to September 2012 Statistics analysis SPSS version17.0 was used for data analysis. Chisquare tests as well as two-tailed Fisher's exact test were used when appropriate to compare categorical variables.P-value of < 0.05was considered as statistically significant. RESULTS During the study period, we only include all the positive urine cultures of E. coli isolatesthat were tested against AST-EXN8card, sixty one cultures, while we exclude any positive urine cultures that were tested against other AST-cards, manually,or show mixed growth. Children were nearly equally infected by both types of E. coli isolates, ESBL-producers 31 (50.8%) and non ESBL-producers30 (49.2%) see table 1.Never the less, There was significantly higher proportion of E. coli isolated from female (83.6%) than male (16.4%) childrenwith UTI in general and also according to the type of E. coli isolates see figure 1. The frequency of antimicrobial resistance for the 16 antimicrobial agents included in AST-EXN8 card against E. coli isolates UTI pathogens (ESBL-producersand Non ESBL-producers) are summarized in Table 2 . ESBL-producing E. coli showed maximum rate resistance to Cefuroxime as well asPiperacillin (100%), Aztreonam, Cefixime, Ceftriaxone plus Levofloxacin (96.8%), Ampicillin/Sulbactam and Cefepime (93.5%), Moxifloxacin (90.3%), while minimum resistance rate was seen with Tigecycline (12.9%),Colistin (3.2%) and meropenem (0%). The Non ESBLproducing E. coli showed maximum resistance rate toCefuroxime (93.3%), Piperacillin along with Chloramphenicol (80%) and Trimethoprim (66.7%), while minimum rate of resistance was seen with Aztreonam, Tigecycline, and Ceftriaxone (6.7%), while no resistance were seen with Cefepime,Colistin,as well as meropenem (0%). ESBL-producing isolates were significantly more resistant than Non-ESBL-producers (p < 0.05) to the following antimicrobials (Ampicillin/Sulbactam, Aztreonam, Cefepime, Cefixime, Ceftriaxone, Levofloxacin, Moxifloxacin, Piperacillin and Tetracycline). Multi-drug resistance (MDR) was higher among ESBL-producing E. coli isolates than non ESBLproducing E.coli isolates in general See figure 3. Figure 1 .Prevalence of ESBL-producers and non ESBL-producer E. coli uropathogenes according to gender. DISCUSSION ESBL-producing E. coli isolates has emerged as serious uropathogens in both in hospital and community acquired UTIs in children and adults, leading to significantly higher treatment failure rate and mortality when compared with non ESBL-producers isolates. 36 The study was conducted to determine the prevalence and resistance profile of ESBL-producers of E.coli isolates in QRAH for children against a certain set of antibiotics using the VITEK 2 system. This study found that ESBL-producers isolates were as high as 50.8%, which is comparable with other studies from Jordan 50.3% 37 or Pakistan (54% -57.4%) [38] [39] [40] , but higher than studies from India (40%) 17 , Tanzania (39.1%) 41 , Iran (21% and  35%) 42,43 , Saudia Arabia (24.5% in children) 44 , Lebanon 17.7% (23.5% from hospitalized children with UTIs and 14.1% from community UTIs), and from other studies in Jordan 10.8%. 45 The prime factors for increasing resistant to 3rd generation cephalosporin or other broad spectrum antibiotics are; the over prescriptions of these antibiotics beside the lack of routine screening for ESBL-producer E.coli or isolation guidelines for the infected patients. 46 38,40,41 ) havebeen also found in different studies. Meropenem showed the best in vitro activity (100%) against of both ESBL-producers and non ESBL-producer isolates; nearly same results (90-100%) were also found in most of studies for cabapenems (imipenem, meropenem, ertapenem). Since carbapenems are relatively safe in children they are still considered the drug of choice for UTIs caused by multi-drug resistant ESBLproducing E. coli. 44, [48] [49] [50] The excellent in vitro activity for Colistin (3.2%) and Tigecycline (12.9%)against both ESBLproducers and non ESBL-producer isolates has been reported in this study, Colistin should be reserved as the last resort against the multi-drug resistant ESBL-producing E. coli 
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Levofloxacin, Moxifloxacinwhich usually not used to treat UTIs, had also showed a higher resistance rate for ESBL-producer E. coli (96.8%, 90.3%), so we should use this class with caution even when we use Ciprofloxacin which considered more safe in younger children than other Quinolones. 47 Chloramphenicol, Tetracycline, and Minocycline were associated with high resistant rate (80.6%, 86.6%, and 71% respectively) against of both ESBL-producers and non ESBL-producer isolates. All are not preferred to be use in UTIs of children because of resistant and safety issues. 38, 47 Trimethoprim resistancewas considered high for both ESBL-producers (87.1%) and non ESBL-producer isolates (66.7%), this may due to long term use as empirical therapy to UTI in some countries,. 38, 40, 41, 47, 49 MDR was found to be higher among ESBLproducing than non ESBL-producing E.coli isolates in this study and in literature. [36] [37] 44 All of the ESBL-producing isolates were found to be resistant to at least (9) antibiotics; at the same time there were 17 ESBL-producing isolates were resistant up to (13-16) antibiotics, while none of non ESBL-producing isolates were found to be resistant to more than (12) antibiotics, and 23 of these isolates where found to be resistant to less than (9) antibiotics; See table 3. The study has some limitations. First,the study was done retrospectively, for that we collect the patient information's and the sample data from the information's that have been provided to the VITEK 2 system, which arein most cases so limited to enable us to differentiate between community and nosocomial UTIs or even the source of the sample within the hospital if. Second, the limited number of samples tested on VITEK 2 system and the antibiotic classes that have been tested, so in future we may need to have a large multi-center studies to address the size of the problem, and to study the resistant patterns to other classes of antibiotics as aminoglycosides and other Quinoloneswhich are more specific and safer to be used in children UTI as ciprofloxacin, or to take in the account the comorbidity factors. But even under all of these limitations we still have a high percentage of ESBL-producers isolates, with high resistant rates; since all of these isolates were resistant to at least nine antibiotics from different classes, moreover these findings are generally consistent with what have been observed in our region or internationally. In summary, the majority of therapy for UTI is empiric, where clinicians not always depend on laboratory guidance, beside the misuse and selfmedication of relatively cheaper antibiotic without any prescription is common in our community. The findings of this study demonstrated an increase in the prevalence of multi-drug resistant ESBL-producers isolates, up to an alarming levels within our hospital region, which limit their treatment options, so we believe it's now a mandatory to perform screening and confirmatory tests for detection of those microorganisms in ourAntibiotic Resistance Patterns of Multidrug Resistant ……… daily routine work, and to provide the clinicians with updated resistant pattern data to choose the best therapeutic option to limit or even prevent their spread within our community. Morepenem has a good activity against ESBL-producers isolates and relatively safe in children to be considered as drug of choice for these microorganisms, where Colistin may consider as the last resort of treatment. 
